Carboplatin and paclitaxel are standard chemotherapy drugs used to treat advanced lung cancer. However, the cancer often continues to grow despite this therapy. The purpose of this study is to find the best dose of an investigational drug called SNX-5422 that can be given with carboplatin and paclitaxel in patients with advanced lung cancer. It is hoped that giving these drugs in combination will be more effective than if they were given alone.
SNX-5422 works against cancer by blocking a protein that cancer cells need called HSP90. SNX-5422 has been assessed alone in patients, but this is the first study to combine SNX-5422 with carboplatin/paclitaxel in patients. SNX-5422 is taken orally (by mouth), while carboplatin and paclitaxel are given intravenously (by vein).